Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.41 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10832787 | 0.86 | PPARA (0.40) | PPARAPPARGCTSKACEPPARD | |
| SCHEMBL30693749 | 0.82 | PPARA (0.41) | PPARAPPARGCTSKACEPPARD | |
| SCHEMBL27349297 | 0.75 | PPARA (0.39) | PPARAPPARGCTSKACEPPARD | |
| SCHEMBL27349789 | 0.75 | APAF1 (0.57) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL16561853 | 0.71 | PPARA (0.45) | PPARAPPARGCTSKACEPPARD | |
| SCHEMBL27349682 | 0.71 | CTSK (0.39) | CTSKCTSSCTSLCTSB | |
| SCHEMBL21315764 | 0.71 | PPARA (0.45) | PPARAPPARGCTSKACEPPARD | |
| SCHEMBL27349689 | 0.71 | CTSK (0.37) | CTSKCTSSCTSLCTSB | |
| SCHEMBL31004972 | 0.70 | AKT1 (0.55) | PPARAPPARGCTSKACEPPARD | |
| SCHEMBL15662587 | 0.70 | ACE (0.48) | PPARAPPARGCTSKACEPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333440-A1 | Azole Tripeptides as Vasodilators | UNIV KANSAS (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333440-A1 | Azole Tripeptides as Vasodilators | VIP, TEK, NPR1 | PPARA 2358/4885PPARG 2996/4885CTSK 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.